Trial Profile

A Phase 1b Open-Label Study of IMSB301 in Subjects With a Type 1 Interferonopathy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMSB 301 (Primary)
Indications Aicardi-Goutieres syndrome; Autoimmune disorders; Neurological disorders; Systemic lupus erythematosus
Focus Adverse reactions
Sponsors ImmuneSensor

Most Recent Events

20 Feb 2026 According to the ImmuneSensor media release, company announced that it has dosed its first patient with IMSB301 in a Phase 1b clinical study being conducted in Australia in patients with genetically defined mutations which drive Aicardi Goutieres Syndrome (AGS) and other Type 1 interferonopathies.
03 Feb 2026 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com